LY03003
Sponsors
Luye Pharma Group Ltd.
Conditions
Parkinson DiseaseParkinson's Disease
Phase 1
Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease
CompletedNCT02055274
Start: 2013-10-31End: 2015-08-31Updated: 2015-10-21
Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease
CompletedNCT03589066
Start: 2018-05-15End: 2018-10-31Updated: 2018-11-08
A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro
CompletedNCT03733561
Start: 2018-11-09End: 2018-12-23Updated: 2021-04-02
A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003
CompletedNCT04627155
Start: 2013-03-15End: 2013-05-20Updated: 2020-11-13
A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD
CompletedNCT04630860
Start: 2020-07-07End: 2022-01-25Updated: 2023-05-16
A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients
CompletedNCT04629404
Start: 2018-11-05End: 2019-03-14Updated: 2020-11-16